Key result
Low molecular weight heparin is the preferred safe treatment and prophylactic agent for pregnant women with acute venous thromboembolism or high-risk thrombophilia.
Why the study?
What are the risk factors, diagnosis, and management strategies for venous thromboembolism in pregnancy?
What are the risk factors, diagnosis, and management strategies for venous thromboembolism in pregnancy?
Low molecular weight heparin is the preferred pharmacological agent for the treatment and prevention of venous thromboembolism in pregnancy due to its safety profile.
No takes yet. Share an insight, caveat, or question.
Supports LMWH preference in pregnancy VTE; leaves open need for prospective trials on dosing and alternatives.
Joon Cheol Park (2016) conducted a review in Pregnancy-related venous thromboembolism. Low molecular weight heparin (LMWH) was evaluated. Low molecular weight heparin is the preferred safe treatment and prophylactic agent for pregnant women with acute venous thromboembolism or high-risk thrombophilia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: